Senseonics Holdings Inc., a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, has announced the retirement of Chief Financial Officer (CFO) R. Don Elsey. He has agreed to remain in his current role and to step down when a replacement is appointed. Elsey will then continue with the company in an advisory role to ensure an orderly transition and completion of the company’s annual U.S. Securities and Exchange Commission filings for the 2018 fiscal year.   “Don has been an important part of the growth of Senseonics as our CFO, and we thank him for his service and high level of professionalism throughout his tenure at Senseonics,” said Tim Goodnow, president and CEO. “Over the past several years, we have successfully completed an IPO and subsequent capital raises, enabling us to execute product launches in Europe, continue our pipeline development initiatives and position the company for a successful commercial launch that is underway in the U.S. Don has contributed much to all of these efforts, and we wish him well in his next pursuits.”   “It has been a pleasure working with the dedicated and talented team at Senseonics,” stated Elsey. “I am proud of what we have accomplished and am confident the company is on a solid path toward delivering life changing technology to people with diabetes.”   Senseonics Holdings Inc. is a medical technology company focused on the design, development, and commercialization of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease. From its inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices. The Eversense CGM System received PMA approval from the U.S. Food and Drug Administration for up to 90 days of continuous use and is available in the United States. The Eversense CGM XL System received CE mark for up to 180 days of continuous use and is available in Europe.